All > Brain Metastases > Brain Cancer

MW151 for Cognitive Impairment

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Cognitive ImpairmentMW151 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study if MW151 can help reduce cognitive dysfunction caused by brain radiation therapy.

Eligible Conditions
  • Cognitive Impairment

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Cognitive Training
1
Mecamylamine Challenge
1
SAGE-718

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 6 months

28 days
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
6 months
Anti-inflammatory effects
Progression-free survival and overall survival
Reduction in cognitive deterioration

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Cognitive Training
1
Mecamylamine Challenge
2
SAGE-718

Trial Design

2 Treatment Groups

Part B: Randomized, placebo-controlled
1 of 2
Part A: Open Label
1 of 2

Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: MW151 · No Placebo Group · Phase 1

Part B: Randomized, placebo-controlled
Drug
Experimental Group · 1 Intervention: MW151 · Intervention Types: Drug
Part A: Open Label
Drug
Experimental Group · 1 Intervention: MW151 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

ImmunoChem Therapeutics, LLCLead Sponsor
National Cancer Institute (NCI)NIH
13,072 Previous Clinical Trials
41,128,878 Total Patients Enrolled
Northwestern MedicineOTHER
8 Previous Clinical Trials
5,293 Total Patients Enrolled
Vinai Gondi, MDPrincipal InvestigatorNorthwestern Medicine
2 Previous Clinical Trials
894 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are willing to and have the capacity to give written informed consent and have signed and dated the informed consent form in accordance with ICH and GCP guidelines.
If the original histologic proof of malignancy is > 5 years, then pathological (i.e., more recent) confirmation is required (e.g., from a systemic metastasis or brain metastasis).
You are of childbearing potential.
You are of childbearing potential and you have no plans for further conception and you practice adequate contraception.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top